Business and Finance

Four pharma commerce experts revisit their 2026 predictions on dealmaking, patient access and commercialization at the year's midpoint.

Novo Nordisk’s complaint argues that Lilly's campaigns leave out information about the most effective injectable doses of Wegovy (semaglutide) and Ozempic (semaglutide), a dispute that could reshape how both companies compete for share in the GLP-1 market.

Ramarketing CEO Emma Banks revisits her "year of two halves" outlook, discussing whether 2026 has followed the same pattern and what she expects for H2.

Eli Lilly's acquisition of AtaiBeckley signals growing pharmaceutical industry commitment to psychedelic-based treatments for treatment-resistant depression.

The API Innovation Center's Gerren McHam on China's new supply chain rules, reshoring policy, and where US drug manufacturing goes next.

Manufacturers must forecast and commercialize products across commercial, government and cash economies to maximize lifetime enterprise value.

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.

PwC projects drug spending will outpace medical trends in 2027, driven by GLP-1s and oncology. Here's what it means for market access.

CMS' proposed framework for 2029 and beyond closes a potential formulation loophole and raises the stakes for launch planning.

As the US and Iran reach a framework agreement to reopen the Strait of Hormuz, Pharmaceutical Commerce breaks down what the deal means for pharmaceutical supply chains.

Will Shrank, MD, breaks down why payers, providers, and manufacturers are all struggling to keep pace with a rapidly expanding cell and gene therapy pipeline — and what it will take to fix it.

A new BGH survey shows some large employers are pulling back on GLP-1 weight-loss coverage in 2027 as rising costs and utilization outpace anticipated savings.

In this week's Pharma Pulse, USP's annual shortages report reveals a sharp rise in drug discontinuations, J&J and Roche commit billions to protein degrader platforms, and more.

As specialty drug spend tops 50% of pharmacy costs, health system specialty pharmacies are evolving from dispensers into longitudinal care management partners.

After adding 160 more drugs, TrumpRx tops 800 prescription offerings. Here's what the latest MFN-driven expansion means for pricing and access.

Novo Nordisk's UAE launch of the Wegovy pill signals a new phase of oral GLP-1 commercialization, with major implications for pharma distribution, channel strategy, and international market access.

Erez Israeli explains how Dr. Reddy's approached commercial readiness for its generic semaglutide launch in Canada and what vertical integration in peptide manufacturing means for the GLP-1 market.

Cencora will support US distribution of Kite's Yescarta and Tecartus, reducing administrative burdens and expanding CAR T-cell therapy access at authorized treatment centers.

FDA approves Shionogi's Xocova, the first oral post-exposure COVID-19 prevention therapy, reducing infection risk by 67% in Phase III trials.

The PBM’s updated commercial formularies reflect negotiated pricing progress with manufacturers.

In this week's Pharma Pulse, House committees advance key legislation targeting PBM kickbacks and pharmacy access, Macfarlane Packaging partners with eutecma to bring modular cold chain solutions to the UK, and more.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

BMS will deploy enterprise AI across functions to streamline workflows, structure field insights, and improve HCP engagement and execution.

In this week's Pharma Pulse, the Trump administration expands TrumpRx to over 600 generics, the Supreme Court clears the way for long-term Medicare drug price negotiations, Eli Lilly moves deeper into genetic medicines with a $202 million acquisition, and the FDA loses more top leadership.